JP7162011B2 - 癌糖ペプチドに対するモノクローナルおよびヒト化抗体 - Google Patents

癌糖ペプチドに対するモノクローナルおよびヒト化抗体 Download PDF

Info

Publication number
JP7162011B2
JP7162011B2 JP2019559134A JP2019559134A JP7162011B2 JP 7162011 B2 JP7162011 B2 JP 7162011B2 JP 2019559134 A JP2019559134 A JP 2019559134A JP 2019559134 A JP2019559134 A JP 2019559134A JP 7162011 B2 JP7162011 B2 JP 7162011B2
Authority
JP
Japan
Prior art keywords
seq
humanized antibody
amino acid
acid sequence
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019559134A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020507338A5 (https=
JP2020507338A (ja
Inventor
ジョウ・ダーパン
パトリック・ヒュー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanocruise Pharmaceutical Ltd
University of Texas System
Original Assignee
Nanocruise Pharmaceutical Ltd
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanocruise Pharmaceutical Ltd, University of Texas System filed Critical Nanocruise Pharmaceutical Ltd
Publication of JP2020507338A publication Critical patent/JP2020507338A/ja
Publication of JP2020507338A5 publication Critical patent/JP2020507338A5/ja
Application granted granted Critical
Publication of JP7162011B2 publication Critical patent/JP7162011B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2019559134A 2017-01-18 2017-01-18 癌糖ペプチドに対するモノクローナルおよびヒト化抗体 Active JP7162011B2 (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2017/071546 WO2018132976A1 (en) 2017-01-18 2017-01-18 Monoclonal and humanized antibodies to a cancer glycopeptide

Publications (3)

Publication Number Publication Date
JP2020507338A JP2020507338A (ja) 2020-03-12
JP2020507338A5 JP2020507338A5 (https=) 2021-04-15
JP7162011B2 true JP7162011B2 (ja) 2022-10-27

Family

ID=62907489

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019559134A Active JP7162011B2 (ja) 2017-01-18 2017-01-18 癌糖ペプチドに対するモノクローナルおよびヒト化抗体

Country Status (5)

Country Link
US (1) US11673966B2 (https=)
EP (1) EP3570881A4 (https=)
JP (1) JP7162011B2 (https=)
CN (1) CN112105384B (https=)
WO (1) WO2018132976A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119431585A (zh) * 2024-11-19 2025-02-14 恩替(苏州)生物科技有限公司 一种抗人muc1抗体的制备方法及应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013500703A (ja) 2009-07-31 2013-01-10 グリコトープ ゲーエムベーハー Ｍｕｃ１抗体
JP2016525560A (ja) 2013-08-02 2016-08-25 サノフイ 固形腫瘍を処置するための抗−Ｍｕｃ１メイタンシノイドイムノコンジュゲート抗体の使用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1182210A1 (en) * 2000-08-17 2002-02-27 BASTERT, Gunter, Prof.Dr.med.Dr.h.c. Epitopes of tumor-associated MUC1 antigen
WO2011127219A1 (en) * 2010-04-06 2011-10-13 Caris Life Sciences Luxembourg Holdings Circulating biomarkers for disease
JP2013540995A (ja) * 2010-08-18 2013-11-07 カリス ライフ サイエンシズ ルクセンブルク ホールディングス エス．アー．エール．エル． 疾患に対する循環バイオマーカー
WO2012115885A1 (en) * 2011-02-22 2012-08-30 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Circulating biomarkers
CN103880956B (zh) * 2014-03-10 2015-12-30 中国人民解放军第四军医大学 抗muc1单克隆抗体及其轻链和重链可变区
US11753619B2 (en) * 2017-02-02 2023-09-12 The Scripps Research Institute Engineered cells and methods of use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013500703A (ja) 2009-07-31 2013-01-10 グリコトープ ゲーエムベーハー Ｍｕｃ１抗体
JP2016525560A (ja) 2013-08-02 2016-08-25 サノフイ 固形腫瘍を処置するための抗−Ｍｕｃ１メイタンシノイドイムノコンジュゲート抗体の使用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Cancer Research, 2012, Vol.72, pp.3324-3336
International Journal of Oncology, 2012, Vol.41, pp.1977-1984

Also Published As

Publication number Publication date
US11673966B2 (en) 2023-06-13
CN112105384A (zh) 2020-12-18
CN112105384B (zh) 2024-08-23
EP3570881A4 (en) 2020-08-19
WO2018132976A1 (en) 2018-07-26
US20200115466A1 (en) 2020-04-16
EP3570881A1 (en) 2019-11-27
JP2020507338A (ja) 2020-03-12

Similar Documents

Publication Publication Date Title
CN107922503B (zh) 一种pdl-1抗体、其药物组合物及其用途
KR102255616B1 (ko) 암의 치료 및/또는 예방용 의약 조성물
RU2756275C2 (ru) Антитела, специфические к рецептору полиовируса (pvr) человека
JP2024059872A (ja) 新規抗ｃｃｒ８抗体
JP2013502913A5 (https=)
WO2017071625A1 (zh) 一种抗pd-1单克隆抗体、其药物组合物及其用途
WO2019003164A1 (en) USE OF ANTI-FAM19A5 ANTIBODIES FOR THE TREATMENT OF CANCERS
HUP0401695A2 (en) Ganglioside-associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumours
US20250042980A1 (en) Complement factor h antibodies
CN116059341A (zh) 药物组合物及用途
JP7377185B2 (ja) 抗ヒトｔｌｒ７抗体
RU2533460C2 (ru) Фармацевтическая композиция для лечения и предупреждения рака
WO2019076277A1 (zh) 抗pd-1抗体和抗lag-3抗体联合在制备治疗肿瘤的药物中的用途
CN113287018A (zh) 抗肿瘤抗原的l2a5抗体或其功能性片段
CN113227148A (zh) 抗gpc3抗体、其抗原结合片段及其医药用途
JP2025148350A (ja) 進展型小細胞肺癌（ｅｓ－ｓｃｌｃ）の治療のための組成物及び方法
JP7162011B2 (ja) 癌糖ペプチドに対するモノクローナルおよびヒト化抗体
US11129893B2 (en) Pharmaceutical composition for treating and/or preventing cancer
CN118108842A (zh) 人源化抗cd24抗体及其应用
WO2016163433A1 (ja) 抗ｆｇｆｒ２抗体と他剤を含む組成物
CN114616245A (zh) 一种抗cd38的抗体及其用途
WO2025146161A1 (en) Antibody, antigen-binding fragment and medical use thereof
RU2782462C1 (ru) Новое антитело против ccr8
CA2983232C (en) Pharmaceutical composition for treating and/or preventing cancer
AU2024308265A1 (en) Anti-her2 antibody for use in treating a low her2 expressing tumor in a subject

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191128

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201208

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20210305

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210831

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220125

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220405

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220804

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220804

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220805

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220825

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220830

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220920

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221017

R150 Certificate of patent or registration of utility model

Ref document number: 7162011

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250